Conversion of Seddon III Nerve Injury to Seddon I/II Nerve Injury

NCT ID: NCT03236064

Last Updated: 2021-01-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-31

Study Completion Date

2024-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the safety and efficacy of PEG 3350 for use in nerve repair.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To demonstrate more rapid and increased return of function by PEG-fusion compared to the best current nerve repair techniques. Neurorrhaphy is not new, being performed now for over 150 years much research has been performed. PEG-Axon fusion on the other hand is relatively new in mammals. Success has already been obtained by two institutions in the rat sciatic nerve transections, demonstrating rapid return of behavioral function4. These however are very controlled injuries and unclear how well these will translate into human studies. For this reason 3 separate clinical studies in increasing order of complexity are proposed.

The first study proposed will be PEG fusion in digital nerve lacerations. Two goals will be demonstrated; improved innervation density and improved innervation threshold compared to traditional repair, and complication rate similar or less than traditional repair. This will demonstrate the safety and efficacy of the procedure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Injury of Other Nerves at Wrist and Hand Level of Unspecified Arm, Initial Encounter

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nerve injury to palm and fingers

Adult patients with acute clean nerve transections of the higher arm injuries in the forearm, wrist, palm and digits of the hand will be recruited

Group Type EXPERIMENTAL

Polyethylene Glycols

Intervention Type DRUG

Demonstrate more rapid and increased return of function by PEG-fusion compared to best current nerve repair techniques

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Polyethylene Glycols

Demonstrate more rapid and increased return of function by PEG-fusion compared to best current nerve repair techniques

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Isolated nerve transections of the digits, forearm, wrist, and palm will be included. * Class III nerve injury (Sunderland's 4th or 5th degree injury) * Nerve injuries that can be prepared using minimal or acceptable tension (according to surgeon discretion). * Pregnant and breastfeeding women cannot participate because of possible unknown and unpredictable risks to the unborn child.

Exclusion Criteria

* Injuries beyond 24 hours will be excluded
Minimum Eligible Age

16 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Neuraptive Therapeutics Inc.

INDUSTRY

Sponsor Role collaborator

WellSpan Health

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Richard C Trevino, MD

Role: PRINCIPAL_INVESTIGATOR

WellSpan York Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

WellSpanYork Hospital

York, Pennsylvania, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Richard C Trevino, MD

Role: CONTACT

717-812-4090

George Bittner, PhD

Role: CONTACT

512-923-3735

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Richard C Trevino, MD

Role: primary

717-812-4090

E

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

696230-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pain In Neuropathy Study
NCT02672059 UNKNOWN